ArticlePharmaceuticals (Basel, Switzerland)2022

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study.

Giuseppe Migliorisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.